Uncategorized
All Patients in Presbia Flexivue Microlens™ FDA Study Complete 6-Month Post-Operative Visits
DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that all 421 subjects treated with the Presbia Flexivue Microlens™ as part of its U.S. Food and Drug Administration (FDA) pivotal study completed their 6-month post-operative visits, one step closer to making the submission of its final PMA module to the FDA in approximately 18 months. The Presbia Flexivue Microlens is a revolutionary optical lens implant for treati
